BOMAC GLUCALPHOS 4 IN 1 METABOLIC TREATMENT FOR CATTLE AND SHEEP

Main information

  • Trade name:
  • BOMAC GLUCALPHOS 4 IN 1 METABOLIC TREATMENT FOR CATTLE AND SHEEP
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BOMAC GLUCALPHOS 4 IN 1 METABOLIC TREATMENT FOR CATTLE AND SHEEP
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CATTLE | SHEEP | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW | EWE | HEIFER | H
  • Therapeutic area:
  • NUTRITION & METABOLISM
  • Therapeutic indications:
  • METABOLIC TREATMENT

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered
  • Authorization number:
  • 36028
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 1 of 9

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

BOMAC GLUCALPHOS

SYNONYMS

Bomaflex Glucalphos 4 in 1

Product Code: 1442

! 09/04

calcium borogluconate injection

PRODUCT USE

For the treatment of milk fever in cattle and sheep and milk fever complicated

by acetonaemia and grass staggers in cattle.

SUPPLIER

Company:BomacLaboratoriesLtd

Address:

Cnr.WiriStationRd&HobillAvenue

ManukauCity

Auckland,

Telephone:+6492623169

Fax:+6492623008

Section 2 - HAZARDS IDENTIFICATION

STATEMENT OF HAZARDOUS NATURE

NON-HAZARDOUS SUBSTANCE. NON-DANGEROUS GOODS. According to

the Criteria of NOHSC, and the ADG Code.

POISONS SCHEDULE

None

RISK

SAFETY

Avoid contact with skin.

Wear eye/face protection.

In case of contact with eyes, rinse with plenty of water and contact Doctor or

Poisons Information Centre.

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

NAME CAS RN %

calcium borogluconate 25

dextrose, as 25

glucose 50-99-7

magnesium hypophosphite 5

gatifloxacin 180200-66-2

No other ingredient information supplied.

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 2 of 9

Section 4 - FIRST AID MEASURES

SWALLOWED

Ifswallowed doNOT inducevomiting.

Ifvomitingoccurs,lean patientforwardorplace onleftside(head-down

position, if possible) to maintain open airway and prevent aspiration.

Observe the patientcarefully.

Nevergiveliquidtoaperson showingsignsofbeing sleepyorwithreduced

awareness; i.e. becoming unconscious.

Givewatertorinse outmouth,thenprovideliquidslowlyand asmuchas

casualty can comfortably drink.

Seekmedicaladvice.

EYE

If this product comes in contact with the eyes:

Immediatelyholdeyelidsapartandflush the eyecontinuouslywithrunning

water.

Ensurecompleteirrigationofthe eye bykeepingeyelidsapartandawayfrom

eye and moving the eyelids by occasionally lifting the upper and lower lids.

ContinueflushinguntiladvisedtostopbythePoisonsInformationCentreora

doctor, or for at least 15 minutes.

Transporttohospitalordoctorwithoutdelay.

Removalofcontactlensesafteraneyeinjuryshould onlybeundertakenby

skilled personnel.

SKIN

If skin contact occurs:

Immediatelyremoveallcontaminated clothing,includingfootwear

Flushskinand hairwithrunning water(and soapifavailable).

Seekmedicalattention ineventofirritation.

INHALED

Iffumesorcombustion productsare inhaled removefromcontaminated area.

Othermeasuresareusuallyunnecessary.

NOTES TO PHYSICIAN

Treatsymptomatically.

Section 5 - FIRE FIGHTING MEASURES

EXTINGUISHING MEDIA

There isnorestrictionon the type ofextinguisherwhichmaybeused.

Use extinguishing media suitable for surrounding area.

FIRE FIGHTING

Usewaterdeliveredasa finespraytocontrolfireand cooladjacentarea.

Do notapproach containerssuspected tobehot.

Coolfireexposed containerswithwatersprayfromaprotectedlocation.

Ifsafetodoso, removecontainersfrompathoffire.

Equipmentshouldbe thoroughlydecontaminated afteruse.

FIRE/EXPLOSION HAZARD

Non combustible.

Notconsidereda significantfirerisk,howevercontainersmayburn.

Decomposition may produce toxic fumes of.

carbon dioxide (CO2).

other pyrolysis products typical of burning organic material.

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 3 of 9

Section 5 - FIRE FIGHTING MEASURES

FIRE INCOMPATIBILITY

Avoid contamination with strong oxidising agents as ignition may result.

HAZCHEM

None

Personal Protective Equipment

PERSONAL PROTECTION EQUIPMENT

Gloves, boots (chemical resistant).

Section 6 - ACCIDENTAL RELEASE MEASURES

EMERGENCY PROCEDURES

MINOR SPILLS

Wipe up.

Avoid contact with skin.

MAJOR SPILLS

Not applicable.

Personal Protective Equipment advice is contained in Section 8 of the MSDS.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

Limitallunnecessarypersonalcontact.

Wearprotectiveclothingwhen riskofexposureoccurs.

Useina well-ventilatedarea.

When handling DONOTeat,drinkorsmoke.

Alwayswashhandswithsoap and waterafterhandling.

Avoidphysicaldamage tocontainers.

Usegoodoccupationalworkpractice.

Observe manufacturer'sstoring and handling recommendations.

SUITABLE CONTAINER

Vial. Ampoule.

STORAGE INCOMPATIBILITY

Avoid contamination of water, foodstuffs, feed or seed.

Avoid reaction with oxidising agents.

STORAGE REQUIREMENTS

Protect from light.

Storeinoriginalcontainers.

Keepcontainerssecurelysealed.

Storeina cool,dry,well-ventilatedarea.

Storeawayfromincompatiblematerialsandfoodstuffcontainers.

Protectcontainersagainstphysicaldamageandcheckregularlyforleaks.

Observe manufacturer'sstoring and handling recommendations.

Store below 25 degC.

Shelf Life: 3 years.

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 4 of 9

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS

Nodataavailableforglucoseas(CAS:50-99-7)/(CAS:492-62-6)/(CAS:492-61-5)

Nodataavailableforgatifloxacinas(CAS:180200-66-2)/(CAS:160738-57-8)/(CAS:

112811-59-3)

Notavailable.Refertoindividualconstituents.

EXPOSURE STANDARDS FOR MIXTURE

"WorstCase"computer-aidedpredictionofspray/mistorfume/dustcomponents

andconcentration:

CompositeExposureStandardforMixture(TWA):0.7059mg/m³.

Operationswhichproduceaspray/mistorfume/dust,introduceparticulatesto

thebreathingzone.

IfthebreathingzoneconcentrationofANYofthecomponentslistedbelowis

exceeded,"WorstCase"considerationsdeemtheindividualtobeoverexposed.

ComponentBreathingZoneppmBreathingZonemg/m³MixtureConc(%).

Component BreathingZone MixtureConc

(mg/m³) (%)

gatifloxacin 0.3529 0.1

glucose 0.3529 0.1

INGREDIENT DATA

GLUCOSE:

Dustsnototherwiseclassified,asinspirabledust;

ESTWA:10mg/m³.

Particulate(insolubleorpoorlysoluble*)NotOtherwiseSpecified(P.N.O.C)

TLVTWA:10mg/m³Inhalableparticulate

TLVTWA:3mg/m³Respirableparticulate

OEL-Sweden,UnitedKingdom:10mg/m³totaldust,5mg/m³respirabledust

These"dusts"havelittleadverseeffectonthelungsanddonotproducetoxic

effectsororganicdisease.Althoughthereisnodustwhichdoesnotevokesome

cellularresponseatsufficientlyhighconcentrations,thecellularresponse

causedbyP.N.O.C.shasthefollowingcharacteristics:

·thearchitectureoftheairspacesremainintact,

·scartissue(collagen)isnotsynthesisedtoanydegree,

·tissuereactionispotentiallyreversible.

ExtensiveconcentrationsofP.N.O.C.smay:

·seriouslyreducevisibility,

·causeunpleasantdepositsintheeyes,earsandnasalpassages,

·contributetoskinormucousmembraneinjurybychemicalormechanicalaction,

perse,orbytherigorousskincleansingproceduresnecessaryfortheir

removal.[ACGIH]

Thislimitdoesnotapply:

·tobriefexposurestohigherconcentrations

·nordoesitapplytothosesubstancesthatmaycausephysiologicalimpairment

atlowerconcentrationsbutforwhichaTLVhasasyettobedetermined.

Thisexposurestandardappliestoparticleswhich

·areinsolubleorpoorlysoluble*inwateror,preferably,inaqueouslung

fluid(ifdataisavailable)and

·havealowtoxicity(i.e..arenotcytotoxic,genotoxic,orotherwise

chemicallyreactivewithlungtissue,anddonotemitionizingradiation,cause

immunesensitization,orcausetoxiceffectsotherthanbyinflammationorbya

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 5 of 9

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

mechanismoflungoverload)

*Noticeofintendedchange.

GATIFLOXACIN:

CELTWA:0.4mg/m³(Bristol-MyersSquibb)

Adherencetotheexposureguidelinewillensuretheworkerisnotexposed

tomorethan2%ofthelowestrecommendedoraltherapeuticdose;this

shouldprotectmostemployeeswhohandlethedrugfromexperiencing

adverseeffectfromthecompound.

PERSONAL PROTECTION

EYE

Nospecialequipmentforminorexposurei.e.whenhandlingsmallquantities.

OTHERWISE:

Safetyglasses withsideshields.

Contactlensespose aspecialhazard;softlensesmayabsorb irritantsandall

lensesconcentratethem.

HANDS/FEET

Nospecialequipmentneededwhenhandlingsmallquantities.

OTHERWISE:Wearchemicalprotectivegloves,eg.PVC.

OTHER

Nospecialequipmentneededwhenhandlingsmallquantities.

OTHERWISE:

Overalls.

Barriercream.

Eyewash unit.

GLOVE SELECTION INDEX

Gloveselectionisbasedonamodifiedpresentationofthe:

"ForsbergClothingPerformanceIndex".

Theeffect(s)ofthefollowingsubstance(s)aretakenintoaccountinthe

computer-generatedselection:

ProtectiveMaterialCPI*.

________________________________

________________________________

*CPI-ChemwatchPerformanceIndex

A:BestSelection

B:Satisfactory;maydegradeafter4hourscontinuousimmersion

C:PoortoDangerousChoiceforotherthanshorttermimmersion

NOTE:Asaseriesoffactorswillinfluencetheactualperformanceoftheglove,

afinalselectionmustbebasedondetailedobservation.-

*Wherethegloveistobeusedonashortterm,casualorinfrequentbasis,

factorssuchas"feel"orconvenience(e.g.disposability),maydictateachoice

ofgloveswhichmightotherwisebeunsuitablefollowinglong-termorfrequent

use.Aqualifiedpractitionershouldbeconsulted.

RESPIRATOR

SelectionoftheClassandTypeofrespiratorwilldependuponthelevelof

breathingzonecontaminantandthechemicalnatureofthecontaminant.

ProtectionFactors(definedastheratioofcontaminantoutsideandinsidethe

mask)mayalsobeimportant.

BreathingZone MaximumProtection Half-face Full-Face

Levelppm(volume) Factor Respirator Respirator

1000 10 -AUSP -

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 6 of 9

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

1000 50 - -AUSP

5000 50 Airline* -

5000 100 - -2P

10000 100 - -3P

100+ Airline**

*-ContinuousFlow**-Continuous-floworpositivepressuredemand.

Thelocalconcentrationofmaterial,quantityandconditionsofusedetermine

thetypeofpersonalprotectiveequipmentrequired.Forfurtherinformation

consultsitespecificCHEMWATCHdata(ifavailable),oryourOccupational

HealthandSafetyAdvisor.

ENGINEERING CONTROLS

Noneundernormaloperatingconditions.

Provideadequateventilationinwarehouseorclosedstorageareas.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE

Clear,almostcolourlesstoyellowliquid.

PHYSICAL PROPERTIES

Liquid.

MolecularWeight:NotApplicable BoilingRange(°C):NotAvailable

MeltingRange(°C):NotAvailable SpecificGravity(water=1):NotAvailable

Solubilityinwater(g/L):NotAvailable pH(assupplied):NotAvailable

pH(1%solution):NotAvailable VapourPressure(kPa):NotAvailable

VolatileComponent(%vol):NotAvailable EvaporationRate:NotAvailable

RelativeVapourDensity(air=1):NotAvailable FlashPoint(°C):NotApplicable

LowerExplosiveLimit(%):NotApplicable UpperExplosiveLimit(%):NotApplicable

AutoignitionTemp(°C):NotApplicable DecompositionTemp(°C):NotAvailable

State:Liquid

log Kow : -3.29

Section 10 - CHEMICAL STABILITY AND REACTIVITY INFORMATION

CONDITIONS CONTRIBUTING TO INSTABILITY

Presence ofincompatiblematerials.

Productisconsideredstable.

Hazardouspolymerisation willnotoccur.

Section 11 - TOXICOLOGICAL INFORMATION

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

Considered an unlikely route of entry in commercial/industrial environments.

Ingestion may result in nausea, abdominal irritation, pain and vomiting.

May cause an erythematous rash followed by desquamation, and stimulation

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 7 of 9

Section 11 - TOXICOLOGICAL INFORMATION

of the nervous system followed by depression.

EYE

The material may be irritating to the eye, with prolonged contact causing

inflammation. Repeated or prolonged exposure to irritants may produce

conjunctivitis.

SKIN

The material may cause skin irritation after prolonged or repeated exposure and

may produce a contact dermatitis (nonallergic). This form of dermatitis is often

characterised by skin redness (erythema) and swelling epidermis. Histologically

there may be intercellular oedema of the spongy layer (spongiosis) and

intracellular oedema of the epidermis.

INHALED

Not normally a hazard due to non-volatile nature of product.

CHRONIC HEALTH EFFECTS

Long-term exposure to the product is not thought to produce chronic effects

adverse to health (as classified by EC Directives using animal models);

nevertheless exposure by all routes should be minimised as a matter of course.

TOXICITY AND IRRITATION

MATERIAL CARCINOGEN SENSITISERSKIN MUTAGEN REPROTOXIN

______________________________ ____________ __________ __________ __________ __________

BomacGlucalphos

glucose

gatifloxacin

Notavailable.Refertoindividualconstituents.

unlessotherwisespecifieddataextractedfromRTECS-RegisterofToxicEffects

ofChemicalSubstances

GLUCOSE:

TOXICITY IRRITATION

Oral(rat)LD50:25800mg/kg Nilreported

Intraperitoneal(mouse)LD50:18000mg/kg

Intravenous(mouse)LD50:9000mg/kg

Specificdevelopmentabnormalitiesreportedinfoetusincludecraniofacial,

hepatobiliary,urogenital.

GATIFLOXACIN:

TOXICITY IRRITATION

Oral(rat)LD50:>2000mg/kg* Skin:non-irritating*

(-)ratLD50:152-196mg/kg* Eye:non-irritating*

Oral(dog)LD50:>1000mg/kg*

Intravenous(dog)LD50:>45mg/kg*

NOTE:Substancehasbeenshowntobemutagenicinatleastoneassay,orbelongs

toafamilyofchemicalsproducingdamageorchangetocellularDNA.

Section 12 - ECOLOGICAL INFORMATION

Refertodataforingredients,whichfollows:

GLUCOSE:

HazardousAirPollutant:No

logPow(Verschueren1983):-3.29

BOD5:0.78

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 8 of 9

Section 12 - ECOLOGICAL INFORMATION

ThOD:1.07

logKow :-3.29

ThOD:1.07

DegradationBiological:sig

GATIFLOXACIN:

Kow:0.132,pH6.9;0.13,pH8

Ecotoxicology:

DaphniamagnaEC50(48h):350mg/l;48hNOEC120mg/l

FishLC50(96h):bluegillsunfish>930mg/l;NOEC540mg/l

Environmentalfate:Thematerialisexpectedtoundergophotolytic

degradation.DegradationispHdependentwithexperimentalhalf-lifes

rangingfrom0.7-2daysatpH5,7and9.

Section 13 - DISPOSAL CONSIDERATIONS

Recyclewhereverpossible.

Consultmanufacturerforrecyclingoptionsorconsultlocalorregionalwaste

management authority for disposal if no suitable treatment or disposal facility

can be identified.

Disposeofby: Burialinalicencedland-fill orIncinerationinalicenced

apparatus (after admixture with suitable combustible material)

Decontaminateemptycontainers.Observe alllabelsafeguardsuntilcontainers

are cleaned and destroyed.

Section 14 - TRANSPORTATION INFORMATION

Shipping Name:

None

Dangerous Goods Class: None, None

UN/NA Number: None

ADR Number: None

Packing Group: None

Labels Required:

Additional Shipping Information:

International Transport Regulations:

IMO: None

HAZCHEM

None

Section 15 - REGULATORY INFORMATION

POISONS SCHEDULE

None

REGULATIONS

glucose (CAS: 50-99-7) is found on the following regulatory lists:

Australian Inventory of Chemical Substances (AICS)

glucose (CAS: 492-62-6) is found on the following regulatory lists:

Australian Inventory of Chemical Substances (AICS)

gatifloxacin (CAS: 180200-66-2) is found on the following regulatory lists:

continued...

BOMAC GLUCALPHOS

ChemWatch Material Safety Data Sheet CHEMWATCH 4632-10

Issue Date: Fri 13-May-2005 CD 2005/2 Page 9 of 9

Section 15 - REGULATORY INFORMATION

Australian Poisons Schedule

Section 16 - OTHER INFORMATION

This document is copyright. Apart from any fair dealing for the purposes of

private study, research, review or criticism, as permitted under the Copyright

Act, no part may be reproduced by any process without written permission from

CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Fri 13-May-2005

Print Date: Tue 14-Jun-2005

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

29-10-2008

Reassessment of reimbursement status for medicinal products in ATC group C08CA

Reassessment of reimbursement status for medicinal products in ATC group C08CA

The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

18-12-2018


Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Europe - EMA - European Medicines Agency